Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of rituximab (Roche Products) to submit evidence of the clinical and cost effectiveness of rituximab in combination with corticosteroids for treatment of an...
المؤلفون الرئيسيون: | Latimer, N, Carroll, C, Wong, R, Tappenden, P, Venning, M, Luqmani, R |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Springer International Publishing
2014
|
مواد مشابهة
-
Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal.
حسب: Latimer, N, وآخرون
منشور في: (2014) -
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
حسب: Guerry, M, وآخرون
منشور في: (2012) -
Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
حسب: Flossmann, O, وآخرون
منشور في: (2006) -
Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis
حسب: Michael A Paley, وآخرون
منشور في: (2019-01-01) -
Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
حسب: Robson, J, وآخرون
منشور في: (2017)